Brief: Vifor Pharma And Angion Report Topline Results From Phase-II Guard Trial Of Ang-3777

Elicio Therapeutics

10/12/2021 06:10

Dec 10 (Reuters) - VIFOR PHARMA AG  VIFN.S :
    * VIFOR PHARMA AND ANGION REPORT TOPLINE RESULTS FROM
PHASE-II
GUARD TRIAL OF ANG-3777 IN CARDIAC SURGERY ASSOCIATED ACUTE
KIDNEY INJURY
    * TRIAL DID NOT MEET ITS PRIMARY ENDPOINT OF PERCENTAGE
INCREASE
IN SERUM CREATININE BASED UPON AREA UNDER CURVE (AUC)
    * ANGION AND VIFOR PHARMA CONTINUE TO REVIEW DATA, BASED ON
SIGNAL
DEMONSTRATED IN CLINICALLY-RELEVANT MAKE90 SECONDARY ENDPOINT

Source text for Eikon:  ID:nBw559rDma 
Further company coverage:  VIFN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))